p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. (Q40036521)
Jump to navigation
Jump to search
scientific article published on April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. |
scientific article published on April 2008 |
Statements
1 reference
p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. (English)
1 reference
Haitian Quan
1 reference
Yongping Xu
1 reference
Liguang Lou
1 reference
1 April 2008
1 reference
1 reference
122
1 reference
8
1 reference
1730-1737
1 reference
1 reference
Identifiers
1 reference
1 reference